Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hiv
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
timely humanimmunodeficiencyvirus confirmation and care after rapid humanimmunodeficiencyvirus self-test: Data from partner services program, New York City. Sexually Transmitted Diseases. 2017;44(10):608–12. Myers JE, El-Sadr Davis OY, Weinstein ER, Remch M, Edelstein A, Khawja A, et al. Availability, accessibility, and price of rapid HIV self-tests, New York City pharmacies, summer 2013. AIDS and Behavior. 2017;21(2):515–24. Estem KS, Catania J, Klausner JD. HIV self-testing: A review of current (...) implementation and fidelity. Current HIV/AIDS Reports. 2016;13(2):107–15. Mathews A, Conserve D, Mason H, Alston L, Rennie S, Tucker J. ‘Informed and empowered’: A mixed-methods study of crowdsourcing contests to promote uptake of HIV self-testing kits among African Americans. Journal of Virus Eradication. 2020;6(2):74–80. Edelstein ZR, Hubbard SJ, Myers JE. Implementation of HIV self-testing program in New York City. JAMA Internal Medicine. 2020;180(4):616. Bjornshagen V, Moseng BU, Ugreninov E. Who do you
: The unmet need for linguistically and culturally competent care for Latinx people living with HIV in a southern region with a low density of Spanish speakers. AIDS Research and Human Retroviruses. 2020. [Epub ahead of print]. Brooks RA, Nieto O, Landrian A, Donohoe TJ. Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: Implications for PrEP adoption among Latino men who have sex with men. AIDS Care. 2019;31(4):427–35. Rhodes SD, Daniel J, Alonzo J, Duck S, Garcia (...) , Bloom FR, Leichliter JS, Montaño J. Outcomes from a community-based, participatory lay health adviser HIV/STD prevention intervention for recently arrived immigrant Latino men in rural North Carolina. AIDS Education & Prevention. 2009;21(Supplement B):103–8. Adam BD, Betancourt G, Serrano Sanchez AA. Development of an HIV prevention and life skills program for Spanish speaking gay and bisexual newcomers. Canadian Journal of Human Sexuality. 2011;20(1):11–17. Zamudio-Haas S, Maiorana A, Gomez LG
Antiretroviral therapies for treating HumanImmunodeficiencyVirus type 1 (HIV-1) infection 1 Driving better decision-making in healthcare Antiretroviral therapies for treating HumanImmunodeficiencyVirus type 1 (HIV-1) infection Technology Guidance from the MOH Drug Advisory Committee Published on 1 September 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended the following antiretroviral therapies (ARTs): ? Nucleoside and nucleotide reverse (...) solution, ritonavir 100 mg tablet; ? Integrase strand transfer inhibitors (INSTIs): dolutegravir 50 mg tablet, raltegravir 400 mg and 600 mg tablets; and ? Fixed-dose combinations: abacavir 600 mg/lamivudine 300 mg tablet, abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg tablet, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet in line with their registered indications for the treatment of HumanImmunodeficiencyVirus type 1 (HIV-1) infection. Subsidy status Raltegravir 400 mg
Fostemsavir (Rukobia) - HIV Drug Approval Package: RUKOBIA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RUKOBIA Company: ViiV Healthcare Company Application Number: 212950 Approval Date: 07/02/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 29
therapy CDC Centers for Disease Control and Prevention CD4 + Cluster-of-Differentiation-4-positive DAIDS Division of AIDS DTG dolutegravir EQ-5D European Quality of Life Questionnaire 5 Dimensions FTC emtricitabine G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) HIVhumanimmunodeficiencyvirusHIV-1 humanimmunodeficiencyvirus type 1 INI integrase inhibitor IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) NNRTI (...) was to assess the added benefit of DTG/3TC in comparison with the appropriate comparator therapy (ACT) in adults and adolescents (12 years of age and older and with a body weight of at least 40 kg) infected with humanimmunodeficiencyvirus type 1 (HIV-1). The HI virus was not to have any known or suspected resistances to the class of integrase inhibitors (INI) or 3TC. Four research questions resulted from the ACT specified by the G-BA. Extract of dossier assessment A19-55 Version 1.0 Dolutegravir
Cabotegravir and rilpivirine (Vocabria/Cabenuva) - HIV?1 Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1
BHIVA guidance for the management of adults with HIV on antiretroviral treatment (ART) during the coronavirus pandemic BHIVA COVID-19 ART guidelines 1 st May 2020 BHIVA guidance for the management of adults with HIV on antiretroviral treatment (ART) during the coronavirus pandemic HIV services have a key role to play in the NHS response to coronavirus and this must be planned. In response to pressures on the NHS, the elective component of our work may be altered. However patients will continue (...) regarding social distancing and shielding should be followed (https://www.gov.uk/government/publications/covid-19-guidance-on- social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for- everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults). There is no evidence to date that people with HIV but without other risks are at increased risk of acquiring or developing complications from COVID-19. The latest evidence is available in the regularly updated joint British HIV
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study. The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations.To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART.Cohort study.HIV clinics in 60 Spanish hospitals between (...) 1 February and 15 April 2020.77 590 HIV-positive persons receiving ART.Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction-confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated
Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. In regions with high burdens of tuberculosis and humanimmunodeficiencyvirus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death.We conducted a 48-week trial of empirical treatment for tuberculosis as compared (...) with treatment guided by testing in HIV-infected adults who had not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter. Patients recruited in Ivory Coast, Uganda, Cambodia, and Vietnam were randomly assigned in a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography) to determine whether treatment for tuberculosis should be started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol
Assessment, Development and Evaluation HPV Human papilloma virus ICER Incremental cost-effectiveness ratio ICO Istituto Catala' d'Oncologia (Spain) LY Life years 9vHPV Nine-valent HPV vaccine PeIN Penile intraepithelial neoplasia PICO Population Intervention Comparison Outcome POTS Postural orthostatic tachycardia syndrome QALY Quality-adjusted life years 6MPI Six-month persistent infection VaIN Vaginal intraepithelial neoplasia VLP Virus-like particle VIN Vulvar intraepithelial neoplasia Glossary Cost (...) the most favorable conditions, e.g. experimental setting. Vaccine hesitancy Delay in acceptance or refusal of vaccines despite availability of vaccination services. Viroprevalence Prevalence of virus in population. SCIENTIFIC ADVICE Guidance on HPV vaccination in EU countries: focus on boys, PLHIV and 9-valent HPV vaccine introduction 1 Executive summary Scope This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas: efficacy/effectiveness of the 9-valent HPV
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Tenofovir alafenamide-emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States.To estimate the greatest possible clinical benefits and economic savings (...) attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF.Cost-effectiveness analysis.Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD).Age-stratified U.S. men who have sex with men (MSM) using PrEP.Five years.Health care sector.Preexposure prophylaxis with F/TAF versus F/TDF.Fractures averted, cases of ESRD averted
of screening strategies for early identification of HIV and HCV infection in injection drug users. PloS One. 2012;7(9). Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: Economic analysis of a randomized controlled trial. Journal of General Internal Medicine. 2010;25(6):556–63. Dowdy DW, Rodriguez RM, Bradley Hare C, Kaplan B. Cost‐effectiveness of targeted humanimmunodeficiencyvirus screening in an urban (...) Cost-effectiveness of rapid point-of-care testing (POCT) programs for HIV Cost-effectiveness of rapid point-of-care testing (POCT) programs for HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Cost-effectiveness of rapid point-of-care testing (POCT) programs for HIV Cost-effectiveness of rapid point-of-care testing (POCT) programs for HIV , , , , Questions What evidence exists regarding the cost-effectiveness of rapid point-of-care testing (POCT) programs for HIV? How
Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas (...) of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available.We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria
care providers caring for persons who have experienced significant exposure to blood and/or body fluids in the work place or community setting. The risk of HumanImmunodeficiencyVirus (HIV) acquisition from a given exposure depends on the likelihood the source has transmissible HIV infection, and the biological risk of HIV transmission based on the exposure that has occurred. This guideline is designed to deal specifically with exposures to HIV and is not applicable to other exposures (...) -arv-guidelines/0 Toronto General Hospital, University Health Network Immunodeficiency Clinic. HIV/HCV Drug Therapy Guide. http://app.hivclinic.ca/ 19 XI REFERENCES 1. Kuhar DT, Henderson DK, Struble KA, et al. for the US Public Health Service Working Group. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HumanImmunodeficiencyVirus and Recommendations for Postexposure Prophylaxis. Infect Control Hosp Epidemiol 2013; 34: 875-92 2. Centers for Disease
with HIV and 9-valent HPV vaccine introduction Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction Technical guidance 30 Mar 2020 Cite: European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction, 2020. Stockholm: ECDC; 2020. This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas (...) Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Guidance on HPV vaccination in EU countries: focus on boys, people living
of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365:1482-1491. 33. Meintjes G, Wilkinson R, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis- associated immune reconstitution inflammatory syndrome. AIDS 2010; 24:2381-2390. 34. Torok ME, Nguyen TB, Tran THC, et al Timing of initiation of antiretroviral therapy in humanimmunodeficiencyvirus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374. 35. Hughes JP (...) OF CONTENTS TABLE 3: Factors to Consider when Selecting an ARV Regimen FACTOR CHARACTERISTICS Regimen Regimen efficacy Genetic barrier to resistance Tolerability and short-term adverse events Potential for drug-drug interactions Toxicity and long-term safety Pill burden and dosing frequency Food requirements Virus Resistance test results Individual HIV infection ? Baseline CD4 cell count and HIV viral load HLA-B*5701 test result Co-existing conditions ? Bone disease (osteoporosis) ? Cardiovascular disease
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. Among some patients with humanimmunodeficiencyvirus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with novel mechanisms of action are needed. Fostemsavir is the prodrug of temsavir, a first-in-class investigational HIV-1 attachment inhibitor.In this ongoing phase 3 trial in 23 countries, we enrolled patients with multidrug (...) -resistant HIV-1 infection in two cohorts, according to their remaining treatment options. In the first cohort, we assigned (in a 3:1 ratio) patients who had the option of using at least one fully active, approved antiretroviral drug in at least one but no more than two antiretroviral classes to add either fostemsavir (at a dose of 600 mg twice daily) or placebo to their failing regimen for 8 days, followed by open-label fostemsavir plus optimized background therapy (randomized cohort). In the second
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. Long-acting injectable regimens may simplify therapy for patients with humanimmunodeficiencyvirus type 1 (HIV-1) infection.We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA level of less than 50 (...) copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary end point was the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm).At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found